Class I recall: Fresenius Kabi USA, LLC: Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Onl

Fresenius Kabi USA, LLC has issued a Class I recall for Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, NDC 65219-594-20. According to the recall notice, an internal investigation at the firm found the product to contain glass particles. The recall pertains to this Rx Only product manufactured by Fresenius Kabi USA, LLC in Lake Zurich, Illinois.

Most relevant for: patients receiving tocilizumab-aazg injection for conditions treated with this IL-6 receptor antagonist

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.